OBJECTIVE： To investigate the effect of X-ray repair cross complementing gene （XRCC1） Arg399Gln （G→A） polymorphism on efficacy of oxaliplatin+fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METHODS： Totally 52 cases of advanced gastric cancer were selected from Hainan Provincial People’s Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin+fluorouracil chemotherapy， for 3 courses （a treatment course lasted for 3 weeks）. The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different genotypes. RESULTS： Among 52 cases of advanced gastric cancer， there were 28 cases of XRCC1 GG genotype （53.8％）， 21 cases of GA genotype （40.4％）， 3 cases of AA genotype （5.8％）， frequencies of which were all in line with Hardy-Weinberg balance （P＞0.05）. Disease control rates of 52 cases were 76.9％， among which disease control rate （92.9％） of GG genotype was significantly higher than that of GA+AA genotype （58.3％）， with statistical significance （P＜0.05）. The average progression free survival of 52 cases was （7.1+1.2） months， among which progression free survival of GG genotype [（8.6±0.8）months] was significantly longer than that of GG+GA genotype [（5.9±0.7）months]， with statistical significance （P＜0.05）. CONCLUSIONS： XRCC1 polymorphism is correlated with efficacy of oxaliplatin+fluorouracil chemotherapy and progression free survival， and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemotherapy and survival.